Supaglutide
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)
Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 2/3 · Completed · Enrollment 547
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Supaglutide RP3D high dose | n/r | n/r | n/r | n/r |
| supaglutide RD3D Low dose | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
Not shown
- Supaglutide RP3D high dose: endpoint not reported
- supaglutide RD3D Low dose: endpoint not reported
- placebo: endpoint not reported